logo BDSP

Base documentaire


  1. Prostate-specific antigen as a screening test for prostate cancer : The United States experience : Prostate-specific antigen : the best prostatic tumor marker.

    Fascicule - En anglais

    Prostate-specific antigen (PSA) is the best single test for the early diagnosis of prostate cancer.

    Screening for prostate cancer by using PSA testing is effective at detecting histologically significant and pathologically organ-confined prostate cancer.

    Serial PSA measurements do not overdetect prostate cancer, at least during a 4-year to 5-year horizon.

    Results of early detection undoubtedly will improve as our ability to use certain PSA transformations such as PSA density, PSA slope, age-specific PSA adjustment, and free versus total serum PSA is characterized better.

    A decrease in disease-specific mortality caused by prostate cancer as a result of PSA screening awaits documentation.

    Mots-clés Pascal : Adénocarcinome, Prostate, Marqueur tumoral, Antigène spécifique prostate, Intérêt, Dépistage, Dosage, Evolution, Age, Norme, Résultat, Homme, Etats Unis, Amérique du Nord, Amérique, Tumeur maligne, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Biologie

    Mots-clés Pascal anglais : Adenocarcinoma, Prostate, Tumoral marker, Prostate specific antigen, Interest, Medical screening, Assay, Evolution, Age, Standards, Result, Human, United States, North America, America, Malignant tumor, Urinary system disease, Male genital diseases, Prostate disease, Biology

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0288592

    Code Inist : 002B14D02. Création : 15/07/1997.